Nevada is currently home to 560 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Las Vegas, Henderson, Reno and Pahrump. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Carson Tahoe Regional Medical Center, Carson City, Nevada
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)
NCT06483945
Recruiting
"To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"
Gender:
ALL
Ages:
2 years and above
Trial Updated:
06/28/2024
Locations: Palm Research Center, Las Vegas, Nevada
Conditions: Diabetes
Register for Updates
A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain (CYPRESS)
NCT05895552
Recruiting
This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of RTA 901 in qualified participants with Diabetic Peripheral Neuropathic Pain (DPNP). Each study part will be randomized into 3 treatment arms; 2 different doses of RTA 901 and RTA 901-maching placebo. The doses of RTA 901 in Part 2 will be selected based on the Exposure-Response (E-R) analyses of data from Part 1. A total of 384 participants wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: Las Vegas Endocrinology, Henderson, Nevada
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
Feasibility and Acceptability of Switching to E-cigarettes Among Cigarette Smokers Engaged in SUD Treatment
NCT05918887
Recruiting
The purpose of the proposed study is to examine the feasibility of integrating a smoking harm reduction program featuring provision of e-cigarettes and tailored instructions to switch into an existing substance use disorder treatment program. This longitudinal study includes three weeks of micro-surveys delivered via text messages to evaluate the intervention's feasibility and acceptability, gather initial effectiveness data, and understand participants' lived experience of smoking and vaping wh... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/27/2024
Locations: University of Nevada, Reno, Reno, Nevada
Conditions: Tobacco Dependence Caused by Cigarettes
Register for Updates
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)
NCT04514653
Recruiting
RGX-314 is being developed as a potential novel one-time gene therapy treatment for the treatment of neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for tre... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
06/25/2024
Locations: Reno Location, Reno, Nevada
Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Register for Updates
A Post-Market Domestic (US) and International Data Collection to Assess the Truliant Knee System
NCT05653102
Recruiting
A Post-Market Domestic (US) and International Data Collection to Assess the Truliant® Knee System
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Nevada Orthopaedic and Spine Center, Las Vegas, Nevada
Conditions: Knee Arthroplasty, Total
Register for Updates
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
NCT04262206
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
06/14/2024
Locations: Reno VA/Sierra Nevada Health Care, Reno, Nevada
Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Register for Updates
A Post-Market Clinical Evaluation of the Treatment of Femur Fractures With the Femoral Nail PF
NCT04015154
Recruiting
This investigation is a prospective, multicenter clinical investigation. It is anticipated that a total of 50 subjects will be enrolled at up to 5 sites. Enrollment is estimated to commence in Q4 of 2018. Neither subjects nor investigators are blinded to treatment and the clinical investigation includes a historical control which will be compared to the Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System. Total duration of enrollment, 12 month follow-up and analysis is expected... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2024
Locations: Reno Orthopedic Clinic, Reno, Nevada
Conditions: Femoral Fracture
Register for Updates
IS-001 Injection in Patients Undergoing Robotic-Assisted Gynecological Surgery
NCT05954767
Recruiting
This study evaluates the safety and efficacy of intravenous injection of IS-001 to aid in intraoperative ureter structure delineation.
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2024
Locations: MountainView Hospital, Las Vegas, Nevada
Conditions: Ureter Injury
Register for Updates
Hydrus® Microstent New Enrollment Post-Approval Study
NCT04553523
Recruiting
The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
05/28/2024
Locations: Center for Sight, Las Vegas, Nevada
Conditions: Primary Open Angle Glaucoma
Register for Updates
Clinical Data Registry of Amblyopia Patients on Luminopia Treatment
NCT06429280
Recruiting
Amblyopia is the most prevalent cause of reduced monocular visual acuity in children and young adults, with estimates of prevalence ranging from 1% to 5%. The most common associated amblyogenic risk factors are uncorrected anisometropia, strabismus, or a combination of these. In addition to reduced visual acuity, amblyopic patients may also have measurable dysfunction of accommodation, fixation, binocularity, vergence, reading fluency, depth perception, and contrast sensitivity. For the first t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/20/2024
Locations: Nevada Eye Physicians, Las Vegas, Nevada
Conditions: Amblyopia
Register for Updates
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT05997017
Recruiting
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Women's Cancer Center of Nevada, Las Vegas, Nevada
Conditions: Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
Register for Updates